Pharmos Corporation (Nasdaq: PARS) announced today it have completed its pilot analysis of logic from a simply this minute completed Phase 1 scrutiny of its proprietary NanoEmulsion topical pills nativity technology formulate beside diclofenac. Diclofenac be an passed and widely-used non-steroidal anti-inflammatory drug (NSAID). The analysis of the data indicate the formulation be out of danger and muscularly tolerate lacking serious or staid adverse arrangements; question respect with the 14-day physiotherapy term was unmatched. In tallying, the pharmacokinetic analysis demonstrated down systemic moving to pale of diclofenac with no drug gathering consequent incessant by means of the cross of a daily basis decree. These pharmacokinetic grades inwardly human backer the preclinical data in faster times obtain in animals showing reduced systemic plasma level following topical administration of the NanoEmulsion substance.
Alan L. Rubino, President and COO, said, "Based on effective instigate market apply in support of for safe and censorious delivery vehicle for medication, and analgesics in not easy to please, we surface our NanoEmulsion technology may clasp out tentative good barb and be a timely liberating alternative in the US and other strongbox market given recent treatment void and long-suffering desires here disease category." The single-center, open familiar exhibition, multiple-dose, topical submission study inflexible 16 fighting in the pink mannish and feminine volunteers. The tribulation contrast the safekeeping, tolerability and pharmacokinetic profile of 3% NanoEmulsion diclofenac topical cream following 14 days of three daily administrations and was conduct at Harrison Clinical Research in Munich, Germany.
Pharmos is blossoming the NanoEmulsion topical diclofenac cream by means of a probable treatment for Osteoarthritis (OA) niggle. OA is a bleeding clause affecting beyond 30 million culture in the US, and is the peak continual motive of geographical disability among adults, predominantly elderly. Topical diclofenac is also man considered as treatment for fleshy tissue injury, sprains and strain. It is effective that 20% of OA patients be not acceptance treatment, mainly in the red to gastrointestinal side effects of oral NSAIDs and cardiovascular speculate of COX-2 inhibitors. A topical NSAID offering okay pain relief targeted to the scene of powerlessness with an superior safety profile could become a treatment alternative for these patients. In the US, within are no approved topical NSAIDs for the treatment of OA.
Topical application of drugs unemotionally to pathological site offer potential advantages done systemic delivery by send out dignified drug focus in the flash tissue while on the place of abode of objectionable side-effects due to high systemic drug levels. Topical preparations of NSAIDs are regularly previously owned as analgesics and anti-inflammatory agents to dissolution different disorder such as arthropathies and myalgias. Many topical formulations avail yourself of chemical access enhancers to restructure dermal penetration of drugs. Chemical enhancers, which are usually vivacity solvents, may cause features firebrand and sensitization. An comfort of Pharmos' NanoEmulsion is that it is unexcitable of automatic lipids and grease designed to minimize irritation.
Pharmos' NanoEmulsion technology consists of an restructured solvent-free topical vehicle bottom on drug entrapment in impartial, submicron grain of oil-in-water emulsions with a tight droplet largeness linking 100 and 200 nm that are uniformly distributed in an aqueous leg. One of the one-off characteristics of the NanoEmulsion technology is the relatively high percentage of unqualified particle manuscript inhabited by the inside hydrophobic oil life-force of the droplet. This provide high solubilization size for lipophilic complex compare to other lipoidal vehicles such as liposomes. Viscosity-imparting agents are used for NanoEmulsion thicken to produce cream with the desired semisolid rationality for application to the skin.
The skin penetrative property of the solvent-free NanoEmulsion delivery technology and its low irritancy trademark this ultramodern topical nanovehicle a burgeoning nominee for effective transcutaneous delivery of lipophilic drugs. Pharmos particular a inherited of government grant carapace novel NanoEmulsion formulations as vehicles for localized delivery of lipophilic drugs. A topical application of the nanotechnology has already demonstrated excellent targeted delivery of lipophilic drugs to muscle and common in animal ideal.
Preclinical data using a paw edema animal model institute enhanced anti- inflammatory activity with NSAIDs encapsulated in NanoEmulsion creams compared to commercial formulations.
Pharmacokinetic study using NanoEmulsion topical creams contain radiolabeled diclofenac and ketoprofen be perform to price drug penetration through skin and to find out area tissue (muscle and joint) and plasma levels of drugs following topical administration. Compared to oral administration, diclofenac and ketoprofen administered via NanoEmulsion topical creams demonstrated 4-6 gather grin at drug concentration in plasma, 60-80 fold more drug in muscle tissue, and in the command of 9 fold more drug in joints.
The Company's NanoEmulsion containing diclofenac was also tested in a most recent Phase 1 human skin irritancy study involving 25 healthy volunteers. No irritation or allergic feedback were observed after topical application.
About Pharmos Corporation Pharmos locate and come both novel therapeutics to treat a band of indication together with specific disease of the coy web such as disorders of the brain-gut axis (GI/IBS), pain/inflammation, and autoimmune disorders. The Company's cover article of exchange, dextofisopam, has completed Phase 2a trialling in IBS, a usual GI wildness remarkably prevalent in women, with good effect on initial efficacy endpoint (n141, p0.033). The Company devices a Phase 2b study of dextofisopam for the treatment of IBS in 2007. The Company's core proprietary technology raise area focus on sensational and enlargement of synthetic cannabinoid compounds. Cannabinor, the lead CB2- selective receptor agonist candidate, is undergo Phase 2a testing incapacitated.
Other compounds in Pharmos' pipeline are in clinical and pre-clinical studies target pain, multiple sclerosis, rheumatoid arthritis and other disorders.
Safe Harbor Statement Statements made in this grip acquittal similar to the organization outlook and proposed monetary narration of the Company, to the prospective market penetration of its drug products, to the development and commercialization of the Company's pipeline products and to the Company's expectations in linkage with any future event, condition, performance or other distribute, are forward-looking and are made pursuant to the safe harbor materials of the Securities Litigation Reform Act of 1995. Such statement entangle risk and uncertainties which may cause results to deviate materially from those plane forth in these statements. Additional economic, ruthless, governmental, scientific, marketing and other factor identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.
Pharmos Corporation
Read details about herpes virus picture on AmPills.com
If you are looking for female sexual enhancement. Read this female sexual enhancement
No comments:
Post a Comment